Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
First Data Cut Shows 83% Efficacy Against Infection
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
You may also be interested in...
The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.
GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.
The European Medicines Agency is this week expected to consider whether the planned marketing applications for investigational products from Iveric Bio, Moderna and Biohaven merit an accelerated assessment.